Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year.
Net income attributable to Gilead was $1 billion, or $0.83 per share, compared to $1.1 billion, or $0.91 per share, last year. Adjusted EPS was $1.34.
For the full year of 2023, GAAP EPS is expected to be $4.50-4.85 while adjusted EPS is estimated to be $6.45-6.80.
Prior performance
Most Popular
Trxade Health Inc. (NASDAQ: MEDS) Q1 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform that digitalizes the retail pharmacy experience. The company has a growing network of suppliers and partnerships with independent
Earnings Preview: Walmart (WMT) expected to report sales and profit gains in Q1
Over the years, Walmart Inc. (NYSE: WMT) has constantly diversified while maintaining its dominance in the retail world. The company is preparing to report financial results for the first three
What to look for when Take-Two Interactive Software (TTWO) reports Q4 2024 earnings results
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) stayed red on Thursday. The stock has dropped 14% over the past three months. The gaming company is scheduled to report its